Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD)

The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium concentration and is the only medication lice...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzoulis, Ploutarchos, Kaltsas, Gregory, Baldeweg, Stephanie E., Bouloux, Pierre-Marc, Grossman, Ashley B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Hyponatraemia in Clinical Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192810/
https://www.ncbi.nlm.nih.gov/pubmed/37214762
http://dx.doi.org/10.1177/20420188231173327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192810/
https://www.ncbi.nlm.nih.gov/pubmed/37214762
http://dx.doi.org/10.1177/20420188231173327

Ejemplares similares